<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173990</url>
  </required_header>
  <id_info>
    <org_study_id>PULSAR-1303</org_study_id>
    <secondary_id>2013-004540-33</secondary_id>
    <nct_id>NCT02173990</nct_id>
  </id_info>
  <brief_title>Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).</brief_title>
  <acronym>PULSAR</acronym>
  <official_title>A Phase 2 Study of Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PULSAR trial is an international, investigator-initiated, single arm open-label phase II&#xD;
      study. The aim of this study is to measure the clinical activity of the combination&#xD;
      FOLFIRI-aflibercept in an homogeneous group of patients with metastatic colorectal cancer,&#xD;
      and treated with a FOLFIRI-aflibercept regimen as first line treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with an unresectable metastatic colorectal carcinoma (mCRC) histologically proven&#xD;
      will be treated with a combination of Irinotecan/bolus-infusion-5-Fluorouracil/Leucovorin&#xD;
      (FOLFIRI regimen) and aflibercept. On day 1 of each cycle patients will receive aflibercept&#xD;
      followed by irinotecan, 5-Fluorouracil (FU) and leucovorin (FOLFIRI regimen). This treatment&#xD;
      will be repeated every 2 weeks until RECIST progression or unacceptable toxicities,&#xD;
      investigator's decision or patient's refusal of further treatment or death, whichever comes&#xD;
      first.&#xD;
&#xD;
      All patients will be assessed during their FOLFIRI-aflibercept with Dynamic Contrast Enhanced&#xD;
      Ultrasound (DCE-US) at baseline, D7 (± 1 day), D28 (± 2 days).&#xD;
&#xD;
      The recruitment period is 24 months. The average duration of the study per patient will be&#xD;
      approximately 12 months, i.e. 3 weeks for screening, 10 months for the combination of FOLFIRI&#xD;
      plus aflibercept and 30 days for follow-up of adverse events after the last dose of study&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">October 22, 2019</completion_date>
  <primary_completion_date type="Actual">November 2, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Rate will be assessed according to RECIST 1.1 with central radiological review.</measure>
    <time_frame>At 10-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) will be determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</measure>
    <time_frame>through the end of study treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Response Rate (BRR)</measure>
    <time_frame>through the end of study treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of PFS according to DCE-US early assessment</measure>
    <time_frame>at day 28 ± 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity</measure>
    <time_frame>at day 7 ± 1, and day 28 ± 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance</measure>
    <time_frame>up to 30 days after the end of the study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Aflibercept-FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On day 1 of each cycle patients will receive aflibercept followed by irinotecan, 5-FU and leucovorin (FOLFIRI regimen). This treatment will be repeated every 2 weeks until RECIST progression or intolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept-FOLFIRI</intervention_name>
    <description>Aflibercept : 4 mg/kg, IV over 1 h on Day 1&#xD;
FOLFIRI :&#xD;
Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :&#xD;
5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :&#xD;
5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.&#xD;
*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²</description>
    <arm_group_label>Aflibercept-FOLFIRI</arm_group_label>
    <other_name>ZALTRAP-FOLFIRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent, and willing and able to comply with protocol&#xD;
             requirements&#xD;
&#xD;
          2. Histologically proven adenocarcinoma of the colon and/or rectum&#xD;
&#xD;
          3. Metastatic disease confirmed clinically/radiologically, and evaluable by dynamic&#xD;
             contrast ultrasound&#xD;
&#xD;
          4. No prior therapy for metastatic disease&#xD;
&#xD;
          5. Duly documented inoperable metastatic disease, i.e. not suitable for complete curative&#xD;
             surgical resection&#xD;
&#xD;
          6. At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic&#xD;
             Resonance Imaging) according to RECIST v1.1&#xD;
&#xD;
          7. Age ≥ 18 years&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2&#xD;
&#xD;
          9. Adequate hematological status: neutrophils (ANC) ≥ 1.5 x109/L; platelets ≥ 100x109/L;&#xD;
             haemoglobin ≥ 9g/ dL&#xD;
&#xD;
         10. Adequate renal function: serum creatinine level &lt; 1.5 mg/dl and Glomerular Filtration&#xD;
             Rate &gt; 50 ml/min by cockroft/ Gault formula&#xD;
&#xD;
         11. Adequate liver function: serum bilirubin ≤ 1.5 x upper normal limit (ULN), alkaline&#xD;
             phosphatase, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) &lt; 5 x&#xD;
             ULN&#xD;
&#xD;
         12. Proteinuria &lt; 2+ (dipstick urinalysis) or ≤ 1g/24 hour&#xD;
&#xD;
         13. Female patients must commit to using reliable and appropriate methods of contraception&#xD;
             until at least 6 months after the end of Aflibercept and 3 months after the end of&#xD;
             Irinotecan (when applicable). Male patients with a partner of childbearing potential&#xD;
             must agree to use contraception in addition to having their partner use another&#xD;
             contraceptive method until at least 6 months after the end of Aflibercept and 3 months&#xD;
             after the end of Irinotecan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled hypercalcemia&#xD;
&#xD;
          2. Uncontrolled systemic hypertension (defined as systolic blood pressure &gt;150 mmHg&#xD;
             and/or diastolic blood pressure &gt;100 mmHg despite medical therapy), or history of&#xD;
             hypertensive crisis, or hypertensive encephalopathy&#xD;
&#xD;
          3. Right-left shunt or severe pulmonary arterial hypertension (pulmonary artery pressure&#xD;
             &gt; 90 mmHg)&#xD;
&#xD;
          4. Respiratory distress syndrome&#xD;
&#xD;
          5. Concomitant antitumor therapy (e.g. chemotherapy, molecular targeted therapy,&#xD;
             immunotherapy)&#xD;
&#xD;
          6. Treatment with any other investigational medicinal product within 28 days prior to&#xD;
             study entry&#xD;
&#xD;
          7. History or presence of Central Nervous System (CNS) metastasis unless adequately&#xD;
             treated (e.g. non irradiated CNS metastasis, seizures not controlled with standard&#xD;
             medical therapy)&#xD;
&#xD;
          8. Gilbert's syndrome&#xD;
&#xD;
          9. Intolerance to atropine sulfate or loperamide&#xD;
&#xD;
         10. Known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
         11. Treatment with Cytochrome P450 3A4 (CYP3A4) inducers unless discontinued &gt; 7 days&#xD;
             prior to registration&#xD;
&#xD;
         12. Any of the following in 3 months prior to inclusion: grade 3-4 gastrointestinal&#xD;
             bleeding (unless due to resected tumor), treatment resistant peptic ulcer disease,&#xD;
             erosive esophagitis or gastritis, infectious or chronic inflammatory bowel disease, or&#xD;
             diverticulitis&#xD;
&#xD;
         13. Other concomitant or previous malignancy, except: i/ adequately treated in-situ&#xD;
             carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin,&#xD;
             iii/ cancer in complete remission for &gt; 5 years,&#xD;
&#xD;
         14. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic&#xD;
             injury within the last 28 days&#xD;
&#xD;
         15. Pregnant or breastfeeding women&#xD;
&#xD;
         16. Patients with known allergy to any excipients to study drugs (including&#xD;
             hypersensitivity to sulphur hexafluoride or to any of the components of SonoVue)&#xD;
&#xD;
         17. History of myocardial infarction and/or stroke or other arterial thrombotic events or&#xD;
             pulmonary embolism or unstable angina pectoris within 6 months prior to registration&#xD;
&#xD;
         18. Poorly controlled cardiac arrhythmias&#xD;
&#xD;
         19. Typical Angina Pectoris at rest within the previous 7 days, or significant worsening&#xD;
             of cardiac symptoms in the previous 7 days, or recent intervention on the coronary&#xD;
             arteries or other factors suggesting clinical instability (eg recent deterioration of&#xD;
             ECG changes in clinical parameters or biological), or acute heart failure, or heart&#xD;
             failure stage III or IV, or severe arrhythmias&#xD;
&#xD;
         20. Bowel obstruction&#xD;
&#xD;
         21. History of severe tumour bleeding or bleeding disorders&#xD;
&#xD;
         22. Poorly controlled anti-coagulation therapy (INR &gt; 3.0 on coumadin or heparin&#xD;
             compounds)&#xD;
&#xD;
         23. Palliative radiation therapy within 4 weeks prior to registration&#xD;
&#xD;
         24. St John's Wort medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine ADENIS, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kremlin Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>colon and/or rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

